Challenge Clear health and economical benefits put pressure on hospitals to offer more laparoscopic procedures. This means longer working hours and more complex surgeries, which require better surgical skills and more skilled physicians. Current technological approaches offer assistance at a high financial cost and therefore eliminate the economical benefits. An innovation is needed which offers labour benefits for the surgeon, brings back economical benefits for the hospital and sustains health benefits for the patient.
Opportunity The global market for laparoscopic devices is projected to reach €11 billion by 2021. Increasing healthcare expenditures demand affordable solutions to reduce cost and increase efficacy. Governments and insurance companies are lowering reimbursement costs and refuse to pay
for expensive new innovations without clear clinical and economical benefits. The demand for affordable solutions that address the 3 pillars -economical, clinical, and labour- in the growing market is an opportunity for Lapara Surgical.
Solution The MIA is a device with benefits for patient, surgeon, and hospital. Economical benefits of laparoscopy, reduced infection risks and hospitalisation, are sustained by a mechanical device that does not require the overall costs of current robotic systems. Clinical benefits of shorter, less painful recovery and less scarring are maintained by a minimally invasive approach. Labour benefits of a short learning curve and improved ergonomics are reached by natural instrument movements and a seated position.
Status A patented Proof of Concept has been used in non-clinical testing, which validated the benefits for surgeons such as ergonomics, and a short learning curve. International partnerships for R&D, manufacturing and distribution are being developed in order to test clinical prototypes in 2018 and rollout commercially in 2019 worldwide.
Financing requirement A total financing requirement of €3,200,000 is needed to bring the product from proof of concept to a clinically tested, and commercial ready instrument. Clinical validation is followed by CE certification to market the product initially in Western Europe and India. The investment is composed as follows: